Pfizer Inc. reported its fourth quarter earnings that surpassed expectations.
The biotech company’s adjusted earnings for the three months ending in December surged +157% from the year-ago quarter to $1.08 per share, beating the Street consensus forecast of 87 cents.
Revenues rose +104% year-over-year to $23.8 billion, compared to analysts' estimates of $24.1 billion.
Looking ahead, Pfizer expects financial year 2022 adjusted earnings in the range of $6.35 to $6.65 per share, compared to the Refinitiv forecast of $6.69. It predicts revenues of between $98 billion and $102 billion.